Company / Financials
Avalo Therapeutics, Inc. Financials
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableRevenue
$59.0K
FY2025 · -86.6% YoY
Net Income
-$78.3M
FY2025 · -122.8% YoY
Profit Margin
-132642.4%
FY2025 · net income / revenue
ROE
-94.2%
FY2025 · return on equity
Total Assets
$116.5M
FY2025
Total Debt
-
FY2025
Equity
$83.0M
FY2025
ROA
-67.2%
FY2025 · return on assets
Statement paths
Metric history
Revenue HistoryTotal revenue from operations$59.0K-86.6% YoYNet Income HistoryProfit after all expenses and taxes-$78.3M-122.8% YoYCost of Revenue HistoryDirect costs of producing goods and services sold-Operating Income HistoryProfit from core business operations before interest and taxes-$72.9M-6.4% YoYSG&A Expense HistorySelling, general, and administrative expenses$22.9M+32.8% YoYR&D Expense HistoryResearch and development spending$50.1M+105.0% YoYIncome Tax HistoryTotal income tax expense$165.0K+44.7% YoYEPS (Basic) HistoryBasic earnings per share-$7.94+93.0% YoYEPS (Diluted) HistoryDiluted earnings per share including stock options and convertibles-$20.91+81.6% YoYShares Outstanding HistoryWeighted average diluted shares outstanding10.5M+1206.1% YoY